(10% Negative) GYRE THERAPEUTICS, INC. (GYRE) Announces Delay in operations Trials for chronic hepatitis B (CHB)-induced liver fibrosis Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
📋 Charles Bland (Director) plans to sell 800 shares of MACOM Technology Solutions Holdings, Inc. (at $358.44 each, total $287K) Filed: May 12, 2026 | ID: 000429